<code id='DB71959F96'></code><style id='DB71959F96'></style>
    • <acronym id='DB71959F96'></acronym>
      <center id='DB71959F96'><center id='DB71959F96'><tfoot id='DB71959F96'></tfoot></center><abbr id='DB71959F96'><dir id='DB71959F96'><tfoot id='DB71959F96'></tfoot><noframes id='DB71959F96'>

    • <optgroup id='DB71959F96'><strike id='DB71959F96'><sup id='DB71959F96'></sup></strike><code id='DB71959F96'></code></optgroup>
        1. <b id='DB71959F96'><label id='DB71959F96'><select id='DB71959F96'><dt id='DB71959F96'><span id='DB71959F96'></span></dt></select></label></b><u id='DB71959F96'></u>
          <i id='DB71959F96'><strike id='DB71959F96'><tt id='DB71959F96'><pre id='DB71959F96'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          leisure time

          author:explore    - browse:616
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          entertainment